There are 2789 resources available
1087P - The importance of anti-PD-1 dosing in the treatment of patients with inoperable or metastatic melanoma
Presenter: Bozena Cybulska-Stopa
Session: ePoster Display
1088P - Adjuvant dabrafenib plus trametinib (DT) treatment completion in patients with resected melanoma in Spain: A retrospective observational study (GEM 1901 - DESCRIBE-AD)
Presenter: Jose Luis Manzano
Session: ePoster Display
1089TiP - Efficacy and tolerability of anti-PD1 antibody in combination with pulsed hedgehog inhibitor in advanced basal cell carcinoma
Presenter: Aurelio Boerlin
Session: ePoster Display
1256P - Capmatinib safety update in MET dysregulated NSCLC from the GEOMETRY mono-1 trial
Presenter: Rebecca Heist
Session: ePoster Display
1257P - Effect of hepatic impairment on tepotinib pharmacokinetics
Presenter: Thomas Marbury
Session: ePoster Display
1092TiP - Investigational (Inv) agents with or without pembrolizumab (pembro) or pembro alone in melanoma (mel): KEYMAKER-U02
Presenter: Reinhard Dummer
Session: ePoster Display
1093TiP - An open-label, multicenter, phase I/II clinical trial of RP1 as a single agent and in combination with nivolumab in patients with solid tumors [IGNYTE]
Presenter: Francesca Aroldi
Session: ePoster Display
1261P - Trastuzumab/pertuzumab combination therapy in advanced pre-treated HER2-mutated non-small cell lung cancer: Results of a DRUP trial cohort
Presenter: Jade van Berge Henegouwen
Session: ePoster Display
1262P - ROS1 resistance mutations and co-occurring genetic alterations to the ROS1 protein-tyrosine kinase inhibitors (crizotinib) in lung cancer
Presenter: Yuqing Weng
Session: ePoster Display